217 related articles for article (PubMed ID: 29183284)
1. Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
Qattan A; Intabli H; Alkhayal W; Eltabache C; Tweigieri T; Amer SB
BMC Cancer; 2017 Nov; 17(1):799. PubMed ID: 29183284
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ
PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
[TBL] [Abstract][Full Text] [Related]
3. Identification of miRNAs Enriched in Extracellular Vesicles Derived from Serum Samples of Breast Cancer Patients.
Ozawa PMM; Vieira E; Lemos DS; Souza ILM; Zanata SM; Pankievicz VC; Tuleski TR; Souza EM; Wowk PF; Urban CA; Kuroda F; Lima RS; Almeida RC; Gradia DF; Cavalli IJ; Cavalli LR; Malheiros D; Ribeiro EMSF
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31963351
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNAs as specific biomarkers for breast cancer detection.
Ng EK; Li R; Shin VY; Jin HC; Leung CP; Ma ES; Pang R; Chua D; Chu KM; Law WL; Law SY; Poon RT; Kwong A
PLoS One; 2013; 8(1):e53141. PubMed ID: 23301032
[TBL] [Abstract][Full Text] [Related]
5. Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer.
Zhao Y; Song Y; Zhang Y; Ji M; Hou P; Sui F
Mol Cell Probes; 2023 Dec; 72():101940. PubMed ID: 37871689
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study.
Marino AL; Evangelista AF; Vieira RA; Macedo T; Kerr LM; Abrahão-Machado LF; Longatto-Filho A; Silveira HC; Marques MM
BMC Cancer; 2014 Oct; 14():739. PubMed ID: 25277099
[TBL] [Abstract][Full Text] [Related]
7. A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer.
Zhao Q; Deng S; Wang G; Liu C; Meng L; Qiao S; Shen L; Zhang Y; Lü J; Li W; Zhang Y; Wang M; Pestell RG; Liang C; Yu Z
Oncotarget; 2016 Apr; 7(16):21865-74. PubMed ID: 26967564
[TBL] [Abstract][Full Text] [Related]
8. An integrated analysis of microRNAs regulating DNA damage response in triple-negative breast cancer.
Kuthethur R; Jerome MS; Subbannayya Y; Chakrabarty S
Breast Cancer; 2023 Sep; 30(5):832-844. PubMed ID: 37344703
[TBL] [Abstract][Full Text] [Related]
9. Dampening enthusiasm for circulating microRNA in breast cancer.
Leidner RS; Li L; Thompson CL
PLoS One; 2013; 8(3):e57841. PubMed ID: 23472110
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of miR-122, miR-574 and miR-375 in Egyptian patients with breast cancer.
Elghoroury EA; Abdelghafar EE; Kamel S; Awadallah E; Shalaby A; El-Saeed GSM; Mahmoud E; Kamel MM; Abobakr A; Yousef RN
PLoS One; 2024; 19(5):e0298536. PubMed ID: 38820252
[TBL] [Abstract][Full Text] [Related]
11. MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study.
Muti P; Donzelli S; Sacconi A; Hossain A; Ganci F; Frixa T; Sieri S; Krogh V; Berrino F; Biagioni F; Strano S; Beyene J; Yarden Y; Blandino G
Carcinogenesis; 2018 Feb; 39(2):98-108. PubMed ID: 29126102
[TBL] [Abstract][Full Text] [Related]
12. miR-877-5p as a Potential Link between Triple-Negative Breast Cancer Development and Metabolic Syndrome.
Moro J; Grinpelc A; Farré PL; Duca RB; Lacunza E; Graña KD; Scalise GD; Dalton GN; Massillo C; Piccioni F; Dimase F; Batagelj E; De Siervi A; De Luca P
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069080
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of circulating exosomal miRNAs in multiple myeloma.
Manier S; Liu CJ; Avet-Loiseau H; Park J; Shi J; Campigotto F; Salem KZ; Huynh D; Glavey SV; Rivotto B; Sacco A; Roccaro AM; Bouyssou J; Minvielle S; Moreau P; Facon T; Leleu X; Weller E; Trippa L; Ghobrial IM
Blood; 2017 Apr; 129(17):2429-2436. PubMed ID: 28213378
[TBL] [Abstract][Full Text] [Related]
14. miRNAs can be generally associated with human pathologies as exemplified for miR-144.
Keller A; Leidinger P; Vogel B; Backes C; ElSharawy A; Galata V; Mueller SC; Marquart S; Schrauder MG; Strick R; Bauer A; Wischhusen J; Beier M; Kohlhaas J; Katus HA; Hoheisel J; Franke A; Meder B; Meese E
BMC Med; 2014 Dec; 12():224. PubMed ID: 25465851
[TBL] [Abstract][Full Text] [Related]
15. QNBC Is Associated with High Genomic Instability Characterized by Copy Number Alterations and miRNA Deregulation.
Bhattarai S; Sugita BM; Bortoletto SM; Fonseca AS; Cavalli LR; Aneja R
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768979
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer.
Anwar SL; Sari DNI; Kartika AI; Fitria MS; Tanjung DS; Rakhmina D; Wardana T; Astuti I; Haryana SM; Aryandono T
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1223-1228. PubMed ID: 31030498
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of blood cells and plasma identifies tissue-specific miRNAs as potential novel circulating biomarkers in cattle.
Ioannidis J; Donadeu FX
BMC Genomics; 2018 Apr; 19(1):243. PubMed ID: 29636028
[TBL] [Abstract][Full Text] [Related]
18. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies.
Pritchard CC; Kroh E; Wood B; Arroyo JD; Dougherty KJ; Miyaji MM; Tait JF; Tewari M
Cancer Prev Res (Phila); 2012 Mar; 5(3):492-497. PubMed ID: 22158052
[TBL] [Abstract][Full Text] [Related]
19. Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics.
Fortis SP; Vaxevanis CK; Mahaira LG; Sofopoulos M; Sotiriadou NN; Dinou A; Arnogiannaki N; Stavropoulos-Giokas C; Thanos D; Baxevanis CN; Perez SA
Cancer Immunol Immunother; 2019 Jan; 68(1):57-70. PubMed ID: 30276443
[TBL] [Abstract][Full Text] [Related]
20. Impact of three miRNA signature as potential diagnostic marker for triple negative breast cancer patients.
Kumar V; Gautam M; Chaudhary A; Chaurasia B
Sci Rep; 2023 Dec; 13(1):21643. PubMed ID: 38062163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
